CollPlant Biotechnologies (CLGN) Downgraded by Zacks Investment Research to Sell

CollPlant Biotechnologies} stock has undergone multiple analysts rating changes in the recent past.  CollPlant Biotechnologies Downgraded by Zacks Investment Research on 10/13/2021. In a note to investors, the firm issued a new rating of Sell. The analysts previously had rating of Hold.

View More CollPlant Biotechnologies (CLGN) Downgraded by Zacks Investment Research to Sell